

1 **TITLE: Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights**
2 **suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients**

3
4 Authors:

5 Adolfo Aleman, MPA^{1,2,3*}
6 Oliver Van Oekelen, MD^{1,2,3*}
7 Bhaskar Upadhyaya, PhD^{2,3}
8 Sarita Agte, MD^{2,3}
9 Katerina Kappes, BS^{2,3}
10 Katherine Beach, BA⁴
11 Komal Srivastava, MS⁴
12 Charles R. Gleason, BS⁴
13 PVI study group
14 Bo Wang, MD²
15 Tarek H. Mouhieddine, MD⁵
16 Kevin Tuballes, MD^{6,7}
17 Daniel Geanon^{6,7}
18 Zenab Khan, BS⁸
19 Ana S. Gonzalez-Reiche, PhD⁸
20 Harm van Bakel, PhD⁸
21 Nicole W. Simons, MA^{8,9}
22 Konstantinos Mouskas, BS^{8,9}
23 Alexander W. Charney, MD, PhD^{8,9,10}
24 Adeeb Rahman, PhD^{6,7,8}
25 Seunghee Kim-Schulze, PhD^{6,7,11}
26 Emilia M. Sordillo, MD, PhD¹²
27 Florian Krammer, PhD^{4,13}
28 Carlos Cordon-Cardo, MD, PhD^{8,11,12}
29 Nina Bhardwaj, MD, PhD^{2,3,7,14}
30 Sacha Gnjatic, PhD^{2,3,6,7,11,12}
31 Miriam Merad, MD, PhD^{2,3,6,7,11}
32 Brian D. Brown, PhD^{6,7,8}
33 Larysa Sanchez, MD^{2,3}
34 Ajai Chari, MD^{2,3}
35 Sundar Jagannath, MD^{2,3}
36 Viviana Simon, MD, PhD^{4,15,16}
37 Ania Wajnberg, MD^{5,17}
38 Samir Parekh, MD^{2,3,7,11}
39

40 Affiliations:

41 ¹ Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai,
42 New York, NY, USA

43 ² Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine
44 at Mount Sinai, New York, NY

45 ³ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

46 ⁴ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY,
47 USA

48 ⁵ Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York,
49 NY, USA

50 ⁶ Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New
51 York, NY, USA

52 ⁷ Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York,
53 NY, USA

54 ⁸ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount
55 Sinai, New York, NY, USA

56 ⁹ Mount Sinai Clinical Intelligence Center, New York, NY, USA

57 ¹⁰ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY,
58 USA

59 ¹¹ Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New
60 York, NY, USA

61 ¹² Department of Pathology, Molecular and Cell-based Medicine, Icahn School of
62 Medicine at Mount Sinai, New York, NY, USA

63 ¹³ Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY,
64 USA

65 ¹⁴ Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

66 ¹⁵ Division of Infectious Disease, Department of Medicine, Icahn School of Medicine at
67 Mount Sinai, New York, NY, USA

68 ¹⁶ Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount
69 Sinai, New York, NY, USA

70 ¹⁷ Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount
71 Sinai, New York, NY, USA

72 *Both authors contributed equally.

73

74 Co-corresponding authors:

75 Ania Wajnberg, MD

76 Samir Parekh, MD

77 Mount Sinai Hospital

78 Icahn School of Medicine

79 One Gustave L. Levy Place, Box 1185

80 New York, NY 10029

81 ania.wajnberg@mountsinai.org

82 samir.parekh@mssm.edu

83 Tel: 212-241-7873

84 Fax: 212-241-3908

85 **SUMMARY (word count: 193)**

86 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are highly
87 effective in healthy individuals. Patients with multiple myeloma (MM) are
88 immunocompromised due to defects in humoral and cellular immunity as well as
89 immunosuppressive therapies. The efficacy after two doses of SARS-CoV-2 mRNA
90 vaccination in MM patients is currently unknown. Here, we report the case of a MM patient
91 who developed a fatal SARS-CoV-2 infection after full vaccination while in remission after
92 B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T treatment.
93 We show that the patient failed to generate antibodies or SARS-CoV-2-specific B and T
94 cell responses, highlighting the continued risk of severe coronavirus disease 2019
95 (COVID-19) in vaccine non-responders. In the largest cohort of vaccinated MM patients
96 to date, we demonstrate that 15.9% lack SARS-CoV-2 spike antibody response more
97 than 10 days after the second mRNA vaccine dose. The patients actively receiving MM
98 treatment, especially on regimens containing anti-CD38 and anti-BCMA, have lower
99 antibody responses compared to healthy controls. Thus, it is of critical importance to
100 monitor this patient population for serological responses. Non-responders may benefit
101 from ongoing public health measures and from urgent study of prophylactic treatments to
102 prevent SARS-CoV-2 infection.

103 **INTRODUCTION (word count: 252)**

104 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines are
105 highly efficacious in preventing coronavirus disease 2019 (COVID-19) morbidity and
106 mortality^{1,2}. Preliminary reports suggest that the antibody response in MM after the initial
107 dose of SARS-CoV-2 mRNA vaccine is attenuated and delayed compared to healthy
108 controls, but information on response after completion of the full two-dose mRNA vaccine
109 regimen in MM patients is currently lacking³⁻⁵. Moreover, studies have not yet examined
110 the T cell response to vaccination in MM patients. The kinetics of the vaccine
111 response in MM patients with prior COVID-19 and impact of treatments on vaccine
112 response are also unknown.

113
114 Here, we present the clinical course of a MM patient who received both vaccine doses
115 after B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T
116 therapy. Despite vaccination, the patient developed a fatal infection with SARS-CoV-2.
117 We show that this patient did not generate circulating anti-spike IgG antibodies, but
118 notably, that the patient also failed to mount detectable SARS-CoV-2-specific B and T
119 cell responses. We contextualize this case by summarizing serological results from a
120 large cohort of 208 vaccinated MM patients compared with 38 age-matched fully
121 vaccinated healthy controls. Importantly, we report on treatment- and disease-related
122 characteristics associated with the absence of serological responses after two doses of
123 mRNA vaccination (Moderna/Pfizer). Taken together, these observations support
124 monitoring of quantitative SARS-CoV-2 spike antibody levels as well as further study of

125 B and T cell responses in the vulnerable MM population to identify patients that remain at
126 risk for severe COVID-19 despite vaccination.

127

128 **RESULTS (word count: 1,214)**

129 Patient A is an IgG kappa MM patient and enrolled in a clinical trial of BCMA-targeted
130 CAR-T cell therapy with a 4-year history of relapsed/refractory myeloma after 5 lines of
131 treatment in the fall of 2020 (Figure 1A). Following apheresis, the patient received
132 lymphodepleting chemotherapy (fludarabine + cyclophosphamide) before CAR-T
133 infusion. Patient A received Pfizer-BioNTech mRNA SARS-CoV-2 vaccination more than
134 three months after CAR-T infusion in accordance with the international guidelines⁶. Blood
135 cell counts (including absolute lymphocyte count) were within normal limits
136 (Supplementary Figure S1), the bone marrow was negative for clonal plasma cells and
137 serologic MM markers were consistent with very good partial response (VGPR) at the
138 time of both vaccine doses. The patient was admitted to the hospital two weeks after
139 receiving the second vaccine dose with progressive dyspnea, hypoxia, and fever. SARS-
140 CoV-2 molecular testing was positive and complete viral genome sequencing revealed
141 the presence of the B.1.1.7 variant. The patient's oxygen requirements escalated and
142 ultimately advanced to mechanical ventilation. Despite best supportive care, including
143 remdesivir, corticosteroids, high-titer convalescent plasma, broad-spectrum antibacterial
144 and antifungal agents, intravenous immunoglobulin and multiple vasopressors, the
145 patient's clinical condition deteriorated, and the patient ultimately passed away.

146

147 We observed the absence of SARS-CoV-2 IgG antibodies following the second vaccine
148 dose in patient A (Figure 1A). Because it has been suggested that T cell responses may
149 offer some protection, even in the absence of circulating antibodies^{7,8}, we examined
150 SARS-CoV-2-specific B and T cell responses after vaccination in patient A compared to
151 a healthy donor (Figure 1B). Flow cytometry revealed complete B cell depletion in the
152 peripheral blood of patient A starting immediately following BCMA-targeted therapy and
153 persisting throughout the two-dose vaccination regimen (Figure 1B, Supplementary
154 Figure S1F). We also confirmed the lack of SARS-CoV-2 spike-specific B cells in patient
155 A in contrast to two vaccinated healthy controls and a previously SARS-CoV-2 infected,
156 recovered and non-vaccinated (i.e. COVID-19 convalescent) peripheral blood
157 mononuclear cell (PBMC) donor, using a mass cytometry (CyTOF) assay (Figure 1B,
158 Supplementary Figure S2)

159
160 Intracellular cytokine measurement after stimulation with either peptides derived from
161 total viral protein or only from spike protein showed complete absence of CD4 and CD8
162 T cell response in patient A despite receiving both vaccine doses. In contrast, we
163 observed SARS-CoV-2 peptide-specific T cell responses in a vaccinated healthy control
164 (Figure 2B) as well as in the COVID-19 convalescent PBMC donor (Supplementary
165 Figure S3A-D). Of note, PBMC of patient A yielded robust recall responses to CEFT
166 peptide pool (CMV, EBV, influenza and tetanus toxin) and SEB (Staphylococcal
167 Enterotoxin B superantigen) highlighting the fact that antigen presentation and T cell
168 activation of patient A were not, per se, compromised (Supplementary Figure S3E). T cell
169 responses were independently confirmed using enzyme-linked immunospot (ELISpot)

170 assays (Supplementary Figure S4) where responses to full-length spike protein was
171 tested in addition to SARS-CoV-2 peptide pools. No IFN- γ spot forming cells (SFC) were
172 observed upon stimulation of PBMC from Patient A with SARS-CoV-2 peptides nor full-
173 length spike protein, whereas IFN- γ SFC were readily detected in the PBMC from the
174 vaccinated healthy controls and from the asymptomatic COVID-19 convalescent PBMC
175 donor.

176
177 Additional controls for our analysis include a fully vaccinated SARS-CoV-2 seronegative
178 MM patient (patient B) on an anti-CD38 monoclonal antibody-containing regimen who
179 also showed negative IgG titers, lack of SARS-CoV-2-specific B and T cell responses and
180 depleted B cells in the peripheral blood (Supplementary Figures S2-4). In contrast,
181 another MM patient (patient C), who received two doses of mRNA vaccine 18 months
182 after BCMA-targeted CAR-T mounted robust antibody titers and demonstrated B and T
183 cell responses to SARS-CoV-2 peptides (Supplementary Figures S2-4). Notably, patient
184 C recovered B cell numbers prior to vaccination (Supplementary Figure S2). Taken
185 together, these results not only suggest that the absence of B cells is responsible for the
186 failure of the SARS-CoV-2 vaccines to induce a B cell response in the form of SARS-
187 CoV-2 antibodies but also point to the possibility that the lack of B cells is involved in the
188 failure to develop proper T cell responses.

189
190 To characterize our finding of persistently negative antibody titers after both SARS-CoV-
191 2 mRNA vaccine doses, we studied serological immune responses in a larger cohort of
192 208 MM patients enrolled in several institutional review board (IRB)-approved

193 observational studies (see Methods for details). All participants had been diagnosed with
194 myeloma and had received, at least, a first dose of mRNA vaccine (70.2% Pfizer-
195 BioNTech, 24.5% NIH-Moderna). At the time of the analysis, 139/208 MM patients
196 (66.8%) had received both mRNA vaccine doses and had SARS-CoV-2 IgG antibody
197 levels measured at least 10 days after receiving the second dose. Of note, 21/139 fully
198 vaccinated MM patients (15.1%) had a previously documented SARS-CoV-2 infection
199 and were seropositive for SARS-CoV-2 prior to immunization. The median age of the MM
200 cohort is 68 years (range 38-93 years) with 58.7% of participants being male. Additional
201 clinical and disease characteristics are outlined in Table 1.

202
203 Of the 139 fully vaccinated patients for whom SARS-CoV-2 antibody titers were available
204 >10 days after the second dose, 117 (84.2%) mounted a measurable SARS-CoV-2 IgG
205 antibody response (i.e. > 5 AU/mL, median 208 AU/mL, range: 7-7882 AU/mL). The 118
206 MM patients without COVID-19 prior to vaccination had 3.6-fold lower antibody levels
207 compared to a fully vaccinated age- and gender-matched control group of health care
208 workers who were all seronegative at the time of vaccination (“control group”) (median of
209 77 AU/mL vs. 279 AU/mL, $p=0.001$, Figure 2A). Notably, antibody levels in the 21 MM
210 vaccine responders that did have evidence of prior COVID-19 were 4.3-fold higher
211 compared to the control group (median of 1199 AU/mL vs. 279 AU/mL, $p<0.001$, Figure
212 2A). Patients receiving MM treatment had significantly lower anti-spike IgG antibody
213 levels after two doses (Supplementary Figure S7L, $p=0.0084$) compared to MM patients
214 not on treatment. Looking at treatment categories, we found significantly lower antibody
215 levels for patients receiving anti-CD38-containing regimens ($p<0.001$) and BCMA-

216 targeted therapy ($p=0.002$) but not for all other treatments ($p=0.95$) compared to patients
217 that are not actively being treated (Figure 2B). Other significant clinical factors that could
218 influence response to vaccination are shown in Supplementary Figure S7.

219
220 Of note, 15.9% of MM patients (22/139) failed to develop SARS-CoV-2 IgG antibodies
221 above the limit of test detection despite having received both doses of mRNA vaccines.
222 We note that 20 of the 22 MM patients that did not develop antibodies were receiving
223 treatment containing either a BCMA-targeted drug or an anti-CD38 monoclonal antibody.
224 Time course of the antibody levels confirmed delayed and suboptimal responses in the
225 majority of MM patients without prior SARS-CoV-2 infection (Figure 2C, Supplementary
226 Figures S5-6).

227
228 Univariate analysis showed a significant association of the following factors with absence
229 of anti-spike IgG after full mRNA vaccination: >3 previous lines of treatment ($p=0.029$),
230 receiving active MM treatment ($p=0.0430$), absence of (stringent) complete response
231 status (sCR/CR) ($p=0.034$), grade 3 lymphopenia ($p=0.001$) and receiving BCMA-
232 targeted therapy ($p<0.001$) (Table 1). Multivariate logistic regression found that, after
233 correcting for age, vaccine type, lines of treatment, time since MM diagnosis, response
234 status and lymphopenia, anti-CD38-containing treatment was borderline non-significant
235 ($p=0.066$, OR=5.098) but BCMA-targeted treatment remained significantly associated
236 with the probability of not developing antibodies after vaccination ($p=0.002$, OR=32.043)
237 (Supplementary Table S1).

238

239 **DISCUSSION (word count: 657)**

240 In our report, patient A died of COVID-19 after being vaccinated with both doses of mRNA
241 vaccine without mounting serologic or cellular adaptive immunity to SARS-CoV-2. Given
242 the recent FDA approvals of a BCMA-targeted antibody-drug conjugate^{9,10} and CAR-T
243 therapy^{11,12}, BCMA-targeted agents are increasingly going to be adopted into standard
244 management of myeloma patients. There is, therefore, an urgent need to study timing of
245 vaccination, SARS-CoV-2 infection prophylaxis and post-vaccine management in this
246 patient population.

247
248 There may be a temporal relationship between BCMA-directed therapy and vaccine
249 efficacy that warrants further research, exemplified by patient A who received the vaccine
250 within 3.5 months of CAR-T therapy and did not mount measurable immune responses.
251 In contrast, patient C who got vaccinated 18 months after CAR-T infusion, had a robust
252 serological response with demonstrated B and T cell activity against SARS-CoV-2. For
253 MM patients undergoing autologous stem cell transplant, we wait 12 months before
254 initiating routine vaccinations to maximize efficacy^{13,14}. We counsel MM patients at our
255 institution to receive COVID-19 vaccination per CDC guidelines¹⁵⁻¹⁷. For the subgroup of
256 patients receiving BCMA-targeted CAR-T treatment, we defer COVID-19 vaccination for
257 three months after CAR-T based on published international guidelines⁶. This may have
258 to be revisited as more data is made available for this patient population.

259
260 Our report provides data of the largest cohort of MM patients with serological response
261 measurements to SARS-CoV-2 mRNA vaccines after completed mRNA SARS-CoV-2

262 vaccination to date. Our finding that over 15% of fully vaccinated MM patients do not have
263 a detectable serologic response, combined with our experience of severe and fatal
264 COVID-19 in one such non-responder highlight the critical need to monitor vaccine
265 response in this high risk population. Non-responders may need to continue public health
266 measures to protect themselves as the pandemic continues and may benefit from study
267 of prophylactic antibody treatments to avoid contracting SARS-CoV-2 or to attenuate
268 disease. We further found that patients with MM on multiple (>3) treatments, current
269 BCMA-targeted treatment and lymphopenia were more likely to have absent antibody
270 response and treatment regimens including anti-CD38 monoclonal antibody led to
271 significantly lower levels of anti-spike IgG. The cohort may contain an overrepresentation
272 of patients on BCMA-targeted treatments as we are a tertiary care center for MM where
273 patients are routinely referred for treatment on clinical trials. Given the risk for developing
274 COVID-19 and need for maintaining masking and other precautionary measures, our
275 findings underscore the need for additional prospective serological monitoring in this
276 subset of MM patients following COVID-19 vaccination.

277
278 In the patients that we studied extensively so far, absence of the CD19+ B cell
279 compartment in the peripheral blood was associated with lack of antigen-specific B and
280 also T cell responses. B cell depletion after anti-CD38 monoclonal antibody treatment
281 regimens has been reported¹⁸⁻²⁰, but the effects of BCMA-targeted treatment modalities
282 on B cell populations (and the general immune composition) is less clear. B cell counts
283 could be measured relatively easily and immunophenotyping in a larger cohort is
284 warranted for independent confirmation of our findings. Furthermore, the mechanism by

285 which BCMA-targeted treatment contributes to lack of T cell vaccine responses requires
286 further in-depth studies since there is no obvious explanation. Reports have shown that,
287 after SARS-CoV-2 infection, T cell responses can be present, even in the absence of
288 circulating antibodies^{7,21}. How this translates to the post-vaccine setting is unclear,
289 especially in patients that are immunocompromised. If B cell counts are indeed transiently
290 reduced after BCMA-targeted treatment, as our findings suggest, it might be beneficial to
291 consider a bridging strategy to protect patients during the critical time before a serological
292 response against SARS-CoV-2 can be mounted.

293
294 The relatively high percentage of vaccine non-responders in the MM population and the
295 potential for cancer-directed therapies to hamper vaccine responses more broadly,
296 support the need for serological monitoring of vaccine responses using quantitative
297 assays, ongoing public health protective measures to avoid contracting SARS-CoV-2,
298 and further study of prophylactic or early treatment modalities against COVID-19 in this
299 high-risk population.

300

301 **REFERENCES**

- 302 1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273
303 SARS-CoV-2 Vaccine. *New England Journal of Medicine* 2020; **384**(5): 403-16.
- 304 2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2
305 mRNA Covid-19 Vaccine. *New England Journal of Medicine* 2020; **383**(27): 2603-15.
- 306 3. Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low Neutralizing Antibody
307 Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2
308 Vaccine Dose. *Blood* 2021.
- 309 4. Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to COVID-
310 19 mRNA vaccines in hematologic malignancies patients. *medRxiv* 2021:
311 2021.04.06.21254949.
- 312 5. Bird S, Panopoulou A, Shea RL, et al. Response to first vaccination against SARS-
313 CoV-2 in patients with multiple myeloma. *The Lancet Haematology*.
- 314 6. Society IM. Recommendations for anti-Covid-19 vaccination in patients with
315 multiple myeloma (MM) and related conditions, AL amyloidosis and other monoclonal
316 gammopathies of clinical significance. 2021. [https://myelomasociety.org/wp-](https://myelomasociety.org/wp-content/uploads/2021/03/PM-COVID-vaccination-in-MM-guidelines-The-Final.pdf)
317 [content/uploads/2021/03/PM-COVID-vaccination-in-MM-guidelines-The-Final.pdf](https://myelomasociety.org/wp-content/uploads/2021/03/PM-COVID-vaccination-in-MM-guidelines-The-Final.pdf).
- 318 7. Schwarzkopf S, Krawczyk A, Knop D, et al. Cellular Immunity in COVID-19
319 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-
320 Specific IgG. *Emerg Infect Dis* 2021; **27**(1).
- 321 8. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-
322 2 in rhesus macaques. *Nature* 2021; **590**(7847): 630-4.

- 323 9. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory
324 multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
325 *Lancet Oncol* 2019.
- 326 10. U.S. Food and Drug Administration CfDEaR. FDA granted accelerated approval to
327 belantamab mafodotin-blmf for multiple myeloma. 2020. [https://www.fda.gov/drug-](https://www.fda.gov/drugs/drug-approvals-and-databases/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma)
328 [approvals-and-databases/fda-granted-accelerated-approval-belantamab-mafodotin-](https://www.fda.gov/drugs/drug-approvals-and-databases/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma)
329 [blmf-multiple-myeloma](https://www.fda.gov/drugs/drug-approvals-and-databases/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma).
- 330 11. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in Relapsed and
331 Refractory Multiple Myeloma. *New England Journal of Medicine* 2021; **384**(8): 705-16.
- 332 12. U.S. Food and Drug Administration CfDEaR. FDA Approves First Cell-Based Gene
333 Therapy for Adult Patients with Multiple Myeloma. 2021. [https://www.fda.gov/news-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma)
334 [events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma)
335 [multiple-myeloma](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma).
- 336 13. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for
337 vaccination of the immunocompromised host. *Clin Infect Dis* 2014; **58**(3): 309-18.
- 338 14. Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant
339 recipients. *Blood* 2016; **127**(23): 2824-32.
- 340 15. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Terpos E, Dimopoulos
341 MA. SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. *HemaSphere* 2021; **5**(3):
342 e547-e.
- 343 16. Ludwig H, Boccadoro M, Moreau P, et al. Recommendations for vaccination in
344 multiple myeloma: a consensus of the European Myeloma Network. *Leukemia* 2021;
345 **35**(1): 31-44.

- 346 17. Dooling K, Marin M, Wallace M, et al. The Advisory Committee on Immunization
347 Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United
348 States, December 2020. *MMWR Morb Mortal Wkly Rep* 2021; **69**(5152): 1657-60.
- 349 18. Casneuf T, Adams HC, van de Donk NWCJ, et al. Deep immune profiling of
350 patients treated with lenalidomide and dexamethasone with or without daratumumab.
351 *Leukemia* 2020.
- 352 19. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune
353 regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple
354 myeloma. *Blood* 2016; **128**(3): 384-94.
- 355 20. Pierceall WE, Amatangelo MD, Bahlis NJ, et al. Immunomodulation in
356 Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with
357 Relapsed/Refractory Multiple Myeloma. *Clinical Cancer Research* 2020; **26**(22): 5895-
358 902.
- 359 21. Sewell HF, Agius RM, Kendrick D, Stewart M. Covid-19 vaccines: delivering
360 protective immunity. *BMJ* 2020; **371**: m4838.

361
362

363 **AUTHOR CONTRIBUTIONS**

364 VS, AW, SP and the PVI study group provided conceptualization, methodology, analysis
365 and resources for this work. SA, KK, KB, KS, CRG were involved in organizational
366 aspects of the clinical studies, patient recruitment, data collection and analysis. OVO, SA,
367 KS, CRG, BW, THM, EMS, FK and CCC were involved in design, data collection,
368 analysis, visualization and interpretation of serological data. AA, BU, KT, DG, AR, SKS
369 and SG were involved in design, execution, analysis, visualization and interpretation of T
370 and B cell assays. ZK, ASGR and HvB were involved in execution, analysis and
371 interpretation of genomic data. NWS, KM, AWC, AR, SKS, SG and MM were involved in
372 design, data collection and analysis of the Mount Sinai COVID-19 biobank data. LS, SJ,
373 AC and SJ were involved in different aspects of patient care. NB, SG, MM, DBD, SJ, VS,
374 AW and SP provided interpretation of the data and conceptualization of the first
375 manuscript draft. OVO, AA, BU, VS, AW and SP contributed to the writing of the first
376 manuscript draft. All coauthors provided critical edits to the initial manuscript draft and
377 approved the final version.

378

379 **ACKNOWLEDGEMENTS**

380 We would like to thank the study participants for their generosity and willingness to
381 participate in longitudinal COVID19 research studies. We would like to acknowledge the
382 clinical and research staff at the Center of Excellence for Multiple Myeloma at Mount Sinai
383 for their help. We acknowledge the lab of Alessandro Sette at the La Jolla Institute for
384 Immunology and the lab of Steven C. Almo at Albert Einstein College of Medicine for
385 sharing reagents that were used in this work.

386

387 PVI study group: Bulbul Ahmed, Hala Alshammary, Dr. Deena Altman, Angela Amoako,
388 Mahmoud Awawda, Carolina Bermúdez-González, Rachel Chernet, Lily Eaker, Shelcie
389 Fabre, Emily. D. Ferreri, Daniel Floda, Dr. Giulio Kleiner, Dr. Denise Jurczynszak, Julia
390 Matthews, Wanni Mendez, Dr. Lubbertus CF Mulder, Jose Polanco, Kayla Russo, Ashley
391 Salimbangon, Dr. Miti Saksena, A. Shin, Levy Sominsky, Sayahi Suthakaran

392

393 **CONFLICT OF INTEREST STATEMENT**

394 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to
395 SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list
396 Florian Krammer as co-inventor. Viviana Simon is listed on the serological assay patent
397 application as co-inventor. Mount Sinai has spun out a company, Kantaro, to market
398 serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer
399 (before 2020) and is currently consulting for Seqirus and Avimex. The Krammer
400 laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Bo Wang reports
401 consulting fees for Sanofi Genzyme. Ajai Chari reports consulting fees for Takeda,
402 Genzyme, Amgen, Bristol Myers Squibb (Celgene) and Janssen. Sundar Jagannath
403 reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm
404 Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. Samir Parekh reports
405 consulting fees from Foundation Medicine. Other authors reported no relevant conflicts
406 of interest.
407

408 **FUNDING STATEMENT**

409 Samir Parekh is supported by National Cancer Institute (NCI) R01 CA244899, CA252222
410 and receives research funding from Amgen, Celgene/BMS, Karyopharm.

411
412 This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation
413 Centers (CIVIC) contract 75N93019C00051, NIAID Center of Excellence for Influenza
414 Research and Surveillance (CEIRS, contract # HHSN272201400008C and
415 HHSN272201400006C), NIAID grants U01AI141990 and U01AI150747, by the generous
416 support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-
417 215611 (5384); and by anonymous donors.

418
419 This effort was supported by the Serological Sciences Network (SeroNet) in part with
420 Federal funds from the National Cancer Institute, National Institutes of Health, under
421 Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this
422 publication does not necessarily reflect the views or policies of the Department of Health
423 and Human Services, nor does mention of trade names, commercial products or
424 organizations imply endorsement by the U.S. Government.

425

426 **FIGURE LEGENDS**

427 **Figure 1: Clinical summary of fatal SARS-CoV-2 infection and absence of spike-**
428 **specific B cells and SARS-CoV-2-specific T cell responses in a B cell maturation**
429 **antigen (BCMA) chimeric antigen receptor (CAR)-T patient after two doses of**
430 **SARS-CoV-2 mRNA vaccine.** (A) Clinical event timeline, showing CAR-T infusion (day
431 0), repeated negative (< 5 AU/mL) SARS-CoV-2 IgG antibody tests (day 76, day 125 and
432 day 151), administration of both doses of the Pfizer-BioNTech mRNA vaccine (day 97
433 and day 125), development of symptomatic COVID-19 (day 132), admission to the
434 intensive care unit (ICU) (day 139) and death (day 160). (B) Lack of B cell and T cell
435 responses to SARS-CoV-2 peptide stimulations, shown by flow cytometry on peripheral
436 blood mononuclear cells (PBMC) in patient A (top, sample collected post vaccine dose 2)
437 and a healthy vaccinated donor (bottom, sample collected post vaccine dose 2). The
438 leftmost column shows a complete depletion of CD19+ B cells in patient A (% of CD45+
439 cells shown) in comparison to the healthy donor. Second column shows the absence of
440 SARS-CoV-2 spike-positive (i.e. spike-specific) B cells in Patient compared to a healthy
441 vaccinated donor (% of CD19+ cells shown). The third column shows absence of spike-
442 specific activated CD4+ T cells (CD4+CD154+IFN- γ +) in patient A in comparison to the
443 healthy vaccinated donor (% of CD3+CD4+ T cells shown). The right plots illustrate
444 relative absence of spike-specific activated CD8+ T cells (CD8+CD107+IFN- γ +) in patient
445 A in comparison to the healthy vaccinated donor (% of CD3+CD8+ T cells shown). T cells
446 were stimulated with CD4+ and CD8+ SARS-CoV-2 peptide pools compared to a healthy
447 vaccinated donor with a seropositive antibody titer at the time of sample collection.

448

449 **Figure 2: Anti-spike (S) IgG antibody responses after two doses of SARS-CoV-2**
450 **mRNA vaccine is delayed and suboptimal or absent in multiple myeloma (MM)**
451 **patients compared to healthy donors.** (A) SARS-CoV-2 anti-S IgG antibody level
452 (shown on log-10 scale) at least 10 days after receiving two doses of SARS-CoV-2 mRNA
453 vaccine in healthy controls without prior COVID-19 infection (gray, left), multiple myeloma
454 (MM) patients without prior COVID-19 infection (blue, center) and MM patients with prior
455 COVID-19 infection (red, right). P-values shown according to non-parametric Mann-
456 Whitney U test. (B) SARS-CoV-2 anti-S IgG antibody level (shown on log-10 scale) at
457 least 10 days after receiving two doses of SARS-CoV-2 mRNA vaccine in MM patients
458 split according to major treatment groups. P-values shown according to the non-
459 parametric Mann-Whitney U test. (C) Qualitative SARS-CoV-2 anti-S IgG antibody
460 measurements of a healthy cohort (left) and a cohort of MM patients (right) showing
461 delayed seroconversion and complete absence of SARS-CoV-2 anti-S IgG antibodies in
462 a subgroup of MM patients. P-values represent comparison between the healthy cohort
463 and MM cohort of the qualitative antibody measurement distribution at the annotated time
464 points using Fisher's Exact Test on a 2x4 contingency table.

465

466 **SUPPLEMENTARY FIGURE LEGENDS**

467 **Supplementary Figure S1: Detailed clinical course and parameters during the time**
468 **period after chimeric antigen receptor (CAR)-T therapy.** (A) Clinical event timeline
469 showing relevant COVID-19-related interventions during ICU admission. (B) Leukocyte
470 count evolution shown on a timeline starting at CAR-T infusion (day 0). Graph shows total
471 white blood cell (WBC) count (green), absolute neutrophil count (blue) and absolute

472 lymphocyte count (red). Vertical line illustrates start date of symptomatic COVID-19
473 infection. Horizontal line is reference line of normal absolute lymphocyte count. (C) M-
474 spike evolution shown on a timeline starting at CAR-T infusion (day 0). Vertical line
475 illustrates start date of symptomatic COVID-19 infection. (D) Temperature curve shown
476 on a timeline starting at CAR-T infusion (day 0). Vertical line illustrates start date of
477 symptomatic COVID-19 infection. (E) Peripheral oxygen saturation shown on a timeline
478 starting at CAR-T infusion (day 0). Vertical line illustrates start date of symptomatic
479 COVID-19 infection. (F) Timeline showing B cells (red) and CAR-T cells (green) as a
480 fraction of total lymphocytes.

481
482 **Supplementary Figure S2: Presence of SARS-CoV-2 spike-specific B cells and T**
483 **and B cell distribution in overall lymphocyte population.** (A) Presence/absence of
484 spike-positive (i.e. spike-specific) B cells by flow cytometry (% of CD19+ cells shown).
485 Presence of spike-positive B cells shown in a COVID-19 convalescent patient 37 days
486 after the start of molecularly confirmed COVID-19 infection. Absence of spike-positive B
487 cells for multiple myeloma (MM) patient B (58 days after vaccination) shown on the
488 second plot from the left side. Absence of spike-positive B cells in MM patient C (43 days
489 before vaccine dose 1) and appearance of spike-positive B cells in the same patient (6
490 days after vaccine dose 2) shown on the right side. Numbers on dot plot represent
491 percentage of spike-positive B cells within the total B cell gate. (B) Severe depletion of B-
492 cells in patient undergoing treatment with a regimen containing anti-CD38 monoclonal
493 antibody post vaccine dose 2, in contrast to patient C who has B cells present one year

494 after CAR-T infusion (sample taken 6 days after vaccine dose 2). Numbers on dot plot
495 represent frequencies of total T (CD3+) and B (CD19+) cells within the lymphocyte gate.

496

497 **Supplementary Figure S3: SARS-CoV-2 specific T cell responses in multiple**
498 **myeloma (MM) patients, vaccinated healthy controls and a COVID-19 convalescent**

499 **healthy donor measured by intracellular cytokine flow cytometry assay.** Peripheral

500 blood mononuclear cells (PBMC) were cultured with either SARS-CoV-2 peptides pools

501 (CD4-MP, CD8-MP-S-MP), positive control CEFT peptide pool, negative control MOG

502 peptide pools or DMSO. Frequencies of IFN- γ -secreting activated CD4⁺ T cells

503 (CD4⁺CD154⁺IFN- γ ⁺) or IFN- γ -secreting activated CD8⁺ T cells (CD8⁺CD107⁺IFN- γ ⁺)

504 under different stimulation conditions measured by Flow Cytometry (% of CD3⁺CD4⁺ T

505 cells or % of CD3⁺CD8⁺ T cells shown). (A,C) Change in the frequency of IFN- γ -secreting

506 activated CD4⁺ T cells prior to receiving mRNA vaccine compared to a time point after

507 vaccine dose 2 in the seropositive (i.e. with detectable titers of anti-spike IgG after

508 vaccination or infection) (A) and seronegative (i.e. without detectable titers of anti-spike

509 IgG) (C) group (% of CD3⁺CD4⁺ T cells shown). (B,D) Change in the frequency of IFN-

510 γ -secreting activated CD8⁺ T cells (CD8⁺CD107⁺IFN- γ ⁺) prior to receiving mRNA

511 vaccine compared to a time point after vaccine dose 2 in the seropositive (B) and

512 seronegative (D) group (% of CD3⁺CD8⁺ T cells shown). Lines denote different patients

513 while symbols illustrate time point in relation to vaccine dose. (E) Flow cytometry dot

514 plots of T cells of patient A, demonstrating functional T cell responses as measured by

515 the presences of IFN- γ -secreting activated CD4⁺ and CD8⁺T cells in response to

516 activation by CEFT and SEB. Numbers denote frequencies of IFN- γ -secreting cells in
517 total CD4⁺ and CD8⁺ T-cell population.

518

519 **Supplementary Figure S4: SARS-CoV-2 specific T cell responses in multiple**
520 **myeloma (MM) patients, vaccinated healthy donors and a COVID-19 convalescent**
521 **healthy donor measured by Elispot assay.** Peripheral blood mononuclear cells
522 (PBMC) were plated at 200,000 (200K) with either SARS-CoV-2 peptides pools (CD4-
523 MP, CD8-MP-S-MP), positive control CEFT peptide pool, negative control MOG peptide
524 pools or DMSO. IFN- γ ⁺ spot forming cells (SFC) were quantified for each condition. (A)
525 Change in IFN- γ ⁺ spots from pre-vaccine to after second dose of vaccine in seropositive
526 subjects (i.e. with detectable titers of anti-spike IgG after vaccination or infection). (B)
527 Lack of in IFN- γ ⁺ spots from seronegative (i.e. without detectable titers of anti-spike IgG)
528 patient A and patient B. Positive control PMA/IONO was plated at 20K to allow on-scale
529 comparison. For visualization purposes 0 spots are plotted as 1 SFC.

530

531 **Supplementary Figure S5: Time course of SARS-CoV-2 anti-spike (S) IgG antibody**
532 **levels in healthy donors versus myeloma patients with/without previous COVID-19**
533 **infection.** Time course of SARS-CoV-2 anti-S IgG antibody levels (shown capped at 125
534 AU/mL) in multiple myeloma (MM) patients with prior COVID-19 infection (red, top), in
535 MM patients without prior COVID-19 infection (blue, center) and in healthy controls
536 without prior COVID-19 infection (gray, bottom). Measurements from the same study
537 participant are linked with dotted lines. Thick lines connect the median at each time point.

538

539 **Supplementary Figure S6: Time course of SARS-CoV-2 anti-spike (S) IgG antibody**
540 **levels in myeloma patients split according to major treatment groups.** Time course
541 of SARS-CoV-2 anti-S IgG antibody levels (shown capped at 125 AU/mL) in multiple
542 myeloma (MM) patients treated with a anti-CD38 monoclonal antibody (mAb)-containing
543 regimen (blue, top), MM patients treated with a BCMA-targeted therapy (second row,
544 orange), MM patients treated with all other treatments (third row, red) and MM patients
545 that were not receiving active treatment at the time of vaccination (bottom, teal).

546

547 **Supplementary Figure S7: Factors univariately associated with levels of SARS-**
548 **CoV-2 anti-spike (S) IgG antibody levels in patients with multiple myeloma (MM)**
549 **more than ten days after receiving two doses of mRNA vaccine.** Boxplots with
550 overlaying jitter plots illustrating the association of different clinical and treatment
551 characteristics with the level of anti-S IgG more than ten days after receiving two doses
552 of mRNA SARS-CoV-2 vaccine. Shown are age less than 65 years (A); male gender (B);
553 vaccine type Pfizer-BioNTech (C); smoldering multiple myeloma (SMM) diagnosis (D);
554 lymphopenia \geq grade 3 (i.e. absolute lymphocyte count $<$ 500/ μ L) (E); immunoparesis (i.e.
555 levels of one or more uninvolved immunoglobulin subtypes below normal) (F); response
556 status according to International Myeloma Working Group (IMWG) criteria of stringent
557 complete response (sCR) or complete response (CR) (G); having received more than 3
558 previous lines of treatment (H); history of autologous stem cell transplant (ASCT) (I); anti-
559 CD38 monoclonal antibody as a part of the current treatment (J); BCMA-targeted
560 treatment as a part of the current treatment (K); and receiving active anti-MM treatment

561 at the time of vaccination (L). P-values represent comparison using the non-parametric
562 Mann-Whitney U test.
563

564 TABLES

565 TABLE 1 – Clinical characteristics of the myeloma cohort and univariate analysis
 566 of disease and treatment characteristics associated with absence of antibody
 567 levels > 10 days after receiving two doses of SARS-CoV-2 mRNA vaccine.

	Full cohort (N=208)		Undetectable anti-S IgG 10d post-dose 2 (N=22)		Detectable anti-S IgG (>5 AU/mL) 10d post-dose 2 (N=117)		p-value
Age (year)	68	[38-93]	70	[43-86]	70	[38-88]	0.4756
Male gender	58.7%	(122)	77.3%	(17)	60.7%	(71)	0.1565
Vaccine Type							0.0905
BNT162b2 (Pfizer-BioNTech)	70.2%	(146)	81.8%	(18)	69.2%	(81)	
mRNA-1273 (Moderna)	24.5%	(51)	18.2%	(4)	28.2%	(33)	
mRNA unspecified	5.3%	(11)	0.0%	(0)	2.6%	(3)	
Disease Isotype							0.6880
IgG	57.2%	(119)	58.3%	(13)	54.7%	(64)	
IgA	23.1%	(48)	33.3%	(4)	26.5%	(31)	
Light chain disease only	17.8%	(37)	8.3%	(5)	15.4%	(18)	
Other	2.4%	(5)	0.0%	(0)	3.4%	(4)	
SMM	5.3%	(11)	0.0%	(0)	4.3%	(5)	1.0000
Active MM							
Time since diagnosis (months)	60	[0-254]	60	[0-187]	61	[0-238]	0.4904
> 3 previous lines of treatment	27.4%	(57)	45.5%	(10)	22.2%	(26)	0.0292
Disease response status:							
CR or sCR	43.3%	(90)	22.7%	(5)	49.6%	(58)	0.0339
VGPR	22.1%	(46)	31.8%	(7)	20.5%	(24)	0.2680
PR or MR	9.1%	(19)	13.6%	(3)	6.8%	(8)	0.3805
SD or PD	14.4%	(30)	22.7%	(5)	12.0%	(14)	0.1847
Unable to assess	11.1%	(23)	9.1%	(2)	11.1%	(13)	1.0000
Neutropenia ≥ G3 (< 1,500/μL)	2.0%	(4/197)	0.0%	(0)	1.8%	(2/109)	1.0000
Lymphopenia ≥ G3 (< 800/μL)	9.7%	(19/196)	36.4%	(8)	7.4%	(8/108)	0.0011
Immunoparesis	88.2%	(181/205)	95.5%	(21)	87.9%	(102/116)	0.4650
Treatment regimen contains:							
Immunomodulatory drug	46.6%	(97)	45.5%	(10)	49.6%	(58)	0.8178
Proteasome inhibitor	27.9%	(58)	36.4%	(8)	29.9%	(35)	0.6170
Steroid	49.5%	(103)	59.1%	(13)	48.7%	(57)	0.4867
Anti-CD38 mAb	45.7%	(95)	59.1%	(13)	45.3%	(53)	0.2540
BCMA-targeted therapy	11.5%	(24)	36.4%	(8)	6.8%	(8)	0.0006
BCMA-targeted bispecific	3.4%	(7)	22.7%	(5)	0.0%	(0)	<0.001
CAR-T cell therapy	8.2%	(17)	13.6%	(3)	6.0%	(7)	0.1957
CAR-T <12 mo before dose 1	3.4%	(7)	9.1%	(2)	1.5%	(2)	0.1179
Other bispecific (non-BCMA)	4.3%	(9)	4.5%	(1)	5.1%	(6)	1.0000
Other therapy (incl. venetoclax, selinexor, elotuzumab, alkylators)	13.9%	(29)	18.2%	(4)	12.0%	(14)	0.7336
Previous ASCT	53.8%	(112)	50.0%	(11)	53.8%	(63)	0.8177
No active treatment	16.3%	(34)	0.0%	(0)	17.1%	(20)	0.0430

Note: values are presented as percentage (*n*) or median [range]; *p*-values according to Mann-Whitney U test for continuous variables and Fisher's exact test for categorical variables. Lab values, disease response status and treatment regimen were registered at the date of administration of the first dose of mRNA vaccine.

Abbreviations: Ig, immunoglobulin; MM, multiple myeloma; SMM, smoldering multiple myeloma; CR, complete response; sCR, stringent complete response; VGPR, very good partial response; PR, partial response; MR, minimal response; SD, stable disease; PD; progressive disease; G3, grade 3 according CTCAE v5.0; G2, grade 2 according CTCAE v5.0; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; ASCT, autologous stem cell transplant; mAb, monoclonal antibody; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor.

568 **SUPPLEMENTARY TABLE S1 – Multivariate logistic regression model with**
569 **absence of detectable IgG antibody levels > 10 days after full vaccination as**
570 **dichotomized outcome.**

Independent variable	p value	OR	95% confidence interval of OR
Age (y)	0.729	1.013	[0.944-1.093]
Vaccine type NIH-Moderna (0/1)	0.394	0.521	[0.098-2.152]
Lines of treatment (n)	0.781	1.037	[0.800-1.365]
Time since MM diagnosis (months)	0.753	1.002	[0.988-1.016]
Response status (s)CR (0/1)	0.007	0.127	[0.024-0.502]
Lymphopenia \geq Grade 3 (0/1)	0.006	9.813	[2.079-56.818]
Current regimen contains:			
BCMA-targeted treatment (0/1)	0.002	32.043	[4.190-360.147]
anti-CD38 monoclonal antibody (0/1)	0.066	5.098	[1.097-42.387]

571





Figure 1: Clinical summary of fatal SARS-CoV-2 infection and absence of spike-specific B cells and SARS-CoV-2-specific T cell responses in a B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T patient after two doses of SARS-CoV-2 mRNA vaccine.








Figure 2: Anti-spike (S) IgG antibody responses after two doses of SARS-CoV-2 mRNA vaccine is delayed and suboptimal or absent in multiple myeloma (MM) patients compared to healthy donors.




Supplementary Figure S1: Detailed clinical course and parameters during the time period after chimeric antigen receptor (CAR)-T therapy.




Supplementary Figure S2: Presence of SARS-CoV-2 spike-specific B cells and T and B cell distribution in overall lymphocyte population.




Supplementary Figure S3: SARS-CoV-2 specific T cell responses in multiple myeloma (MM) patients, vaccinated healthy donors and a COVID-19 convalescent healthy donor measured by Intracellular Cytokine Flow Cytometry Assay




Supplementary Figure S4: SARS-CoV-2 specific T cell responses in multiple myeloma (MM) patients, vaccinated healthy donors and a COVID-19 convalescent healthy donor measured by Elispot Assay.



Supplementary Figure S5: Time course of SARS-CoV-2 anti-spike (S) IgG antibody levels in healthy donors versus myeloma patients with/without previous COVID-19 infection.



Supplementary Figure S6: Time course of SARS-CoV-2 anti-spike (S) IgG antibody levels in myeloma patients split according to major treatment groups.



Supplementary Figure S7: Factors univariately associated with levels of SARS-CoV-2 anti-spike (S) IgG antibody levels in patients with multiple myeloma (MM) more than ten days after receiving two doses of mRNA vaccine.